PDS Biotechnology reported promising interim data of the PDS0101 and Pembrolizumab combo in HNSCC

Mirati Therapeutics’ SAPPHIRE study evaluating Sitravatinib + Opdivo missed the primary endpoint in NSCLC

Pembrolizumab and Lenvatinib combination received a NICE recommendation for Endometrial Cancer

China NMPA accepted sNDA for Junshi Bio’s Toripalimab and Chemo combo in TNBC

Lumicell’s Breast Cancer imaging agent LUMISIGHT received a priority review from the FDA

FDA granted IND clearance for IDEAYA’s Phase 1/2 MTAP-deletion trials in solid tumors